Kongressberichte & Archiv

11th European Breast Cancer Conference (EBCC-11)

Prof. Dr. med. Nadia Harbeck, München

Prof. Dr. med. Nadia Harbeck, München

Interview geführt von Renate Haidinger, Brustkrebs Deutschland e.V. zu folgenden Themen:

CDK4/6 Inhibitoren: Wo stehen wir heute?
EBCC11 Keynote Lecture - Therapieansprechen

News

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

31-01-2020 22:56
The combination of TAS-102 plus bevacizumab could be a new treatment option for patients with refractory metastatic colorectal cancer and could be a practice-changing development (cited in the Lancet Oncology)
Weiterlesen ...
TRENDING NOW ON JAMA ONCOLOGY:

09-01-2020 17:50
Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Breast Cancer That Progressed on Endocrine Therapy
Establishing a SAKK Working Group for Cellular Therapies

19-12-2019 22:08
PRESS RELEASE
Date Bern, December 12, 2019
Weiterlesen ...